Fig. 1From: Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBMGAPDH-normalized mRNA expression of inflammatory and degenerative markers. The mRNA-expression was assessed by quantitative (real-time) polymerase chain reaction relative to GAPDH in skeletal muscle from patients with inclusion body myositis (IBM) before (pre) and after (post) treatment with alemtuzumab. Subgroups are differentially labeled as responders (red) and non-responders (blue)Back to article page